- Home
- VTYX vs PYXS Comparison
VTYX vs PYXS Comparison
Compare VTYX & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- PYXS
- Stock Information
- Founded
- VTYX 2018
- PYXS 2018
- Country
- VTYX United States
- PYXS United States
- Employees
- VTYX N/A
- PYXS 54
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- PYXS Health Care
- Exchange
- VTYX Nasdaq
- PYXS Nasdaq
- Market Cap
- VTYX 148.4M
- PYXS 124.9M
- IPO Year
- VTYX 2021
- PYXS 2021
- Fundamental
- Price
- VTYX $1.73
- PYXS $2.10
- Analyst Decision
- VTYX Buy
- PYXS Strong Buy
- Analyst Count
- VTYX 5
- PYXS 7
- Target Price
- VTYX $8.40
- PYXS $9.57
- AVG Volume (30 Days)
- VTYX 1.1M
- PYXS 1.5M
- Earning Date
- VTYX 11-07-2024
- PYXS 11-12-2024
- Dividend Yield
- VTYX N/A
- PYXS N/A
- EPS Growth
- VTYX N/A
- PYXS N/A
- EPS
- VTYX N/A
- PYXS N/A
- Revenue
- VTYX N/A
- PYXS $16,146,000.00
- Revenue This Year
- VTYX N/A
- PYXS N/A
- Revenue Next Year
- VTYX N/A
- PYXS N/A
- P/E Ratio
- VTYX N/A
- PYXS N/A
- Revenue Growth
- VTYX N/A
- PYXS N/A
- 52 Week Low
- VTYX $1.67
- PYXS $1.35
- 52 Week High
- VTYX $11.48
- PYXS $6.85
- Technical
- Relative Strength Index (RSI)
- VTYX 30.10
- PYXS 24.53
- Support Level
- VTYX $2.10
- PYXS $3.88
- Resistance Level
- VTYX $2.36
- PYXS $4.31
- Average True Range (ATR)
- VTYX 0.12
- PYXS 0.36
- MACD
- VTYX -0.05
- PYXS -0.17
- Stochastic Oscillator
- VTYX 8.76
- PYXS 4.01
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.